Coya Therapeutics reported total assets of $47.31M and total liabilities of $4.03M for the quarter ended Jun 2026, up 41.4% year over year. This balance sheet covers 19 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Current Assets | |||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 4.34M | 5.93M | 16.32M | 13.10M | 10.89M | 32.63M | 36.00M | 36.60M | 31.10M | 38.34M | 35.53M | 29.80M | 28.13M | 46.82M | 50.72M | 43.20M | |||
| Cash & Current Investments | 4.34M | 5.93M | 16.32M | 13.10M | 10.89M | 32.63M | 36.00M | 36.60M | 31.10M | 38.34M | 35.53M | 29.80M | 28.13M | 46.82M | 50.72M | 43.20M | |||
| Prepaid Assets | 0.24M | 1.25M | 1.01M | 1.29M | 0.94M | 1.07M | 1.34M | 3.31M | 4.45M | 5.97M | 2.84M | 3.67M | 3.89M | 3.12M | 2.54M | 3.88M | |||
| Current Assets | 4.58M | 7.18M | 17.33M | 14.39M | 11.82M | 41.20M | 37.33M | 39.89M | 35.51M | 44.31M | 38.37M | 33.43M | 32.02M | 49.94M | 53.26M | 47.06M | |||
| Non-Current Assets | |||||||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 0.12M | 0.09M | 0.09M | 0.08M | 0.07M | 0.07M | 0.06M | 0.05M | 0.05M | 0.04M | 0.03M | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M | |||
| Other Non-Current Assets | 0.09M | 1.12M | 0.24M | ||||||||||||||||
| Non-Current Assets | 0.21M | 1.21M | 0.09M | 0.08M | 0.07M | 0.07M | 0.06M | 0.05M | 0.05M | 0.04M | 0.03M | 0.02M | 0.02M | 0.01M | 0.01M | 0.25M | |||
| Assets | 4.79M | 8.40M | 17.42M | 14.47M | 11.90M | 41.26M | 37.39M | 39.94M | 35.55M | 44.35M | 38.40M | 33.45M | 32.04M | 49.95M | 53.27M | 47.31M | |||
| Liabilities | |||||||||||||||||||
| Current Liabilities | |||||||||||||||||||
| Accounts Payables | 0.86M | 1.82M | 0.54M | 0.24M | 0.63M | 1.16M | 1.59M | 1.88M | 0.34M | 1.59M | 1.69M | 0.93M | 1.11M | 1.06M | 0.95M | 1.09M | |||
| Payables | 0.86M | 1.82M | 0.54M | 0.24M | 0.63M | 1.16M | 1.59M | 1.88M | 0.34M | 1.59M | 1.69M | 0.93M | 1.11M | 1.06M | 0.95M | 1.09M | |||
| Accumulated Expenses | 0.29M | 2.01M | 0.72M | 0.98M | 1.17M | 2.97M | 2.04M | 1.00M | 1.41M | 1.39M | 1.81M | 2.84M | 1.64M | 3.61M | 1.36M | 1.19M | |||
| Other Accumulated Expenses | 0.04M | ||||||||||||||||||
| Current Taxes | 0.72M | 0.72M | |||||||||||||||||
| Current Deferred Revenue | 0.92M | 0.69M | 0.94M | 0.57M | 0.85M | 0.84M | 0.73M | 0.92M | 1.20M | 1.24M | 1.23M | ||||||||
| Total Current Liabilities | 1.15M | 3.82M | 1.27M | 1.22M | 1.81M | 5.05M | 4.32M | 3.83M | 2.32M | 3.82M | 4.34M | 4.50M | 3.67M | 5.87M | 3.55M | 3.51M | |||
| Non-Current Liabilities | |||||||||||||||||||
| Convertible Debt | 12.97M | ||||||||||||||||||
| Non-Current Deffered Revenue | 0.57M | 0.68M | 0.86M | 1.22M | 0.95M | 0.69M | 0.64M | 1.09M | 1.05M | 0.75M | 0.52M | ||||||||
| Total Liabilities | 1.15M | -1.96M | 1.41M | 5.36M | 16.79M | 1.27M | 1.22M | 1.81M | 5.63M | 5.00M | 4.68M | 3.54M | 4.77M | 5.04M | 5.14M | 4.76M | 6.92M | 4.30M | 4.03M |
| Shareholder's Equity | |||||||||||||||||||
| Common Equity | 3.64M | 1.96M | -1.41M | -5.36M | -8.39M | 16.15M | 13.25M | 10.09M | 35.64M | 32.39M | 35.26M | 32.01M | 39.58M | 33.37M | 28.31M | 27.28M | 43.03M | 48.97M | 43.28M |
| Liabilities and Shareholders Equity | 4.79M | 8.40M | 17.42M | 14.47M | 11.90M | 41.26M | 37.39M | 39.94M | 35.55M | 44.35M | 38.40M | 33.45M | 32.04M | 49.95M | 53.27M | 47.31M | |||
| Retained Earnings | -5.62M | -17.87M | 36.76M | 36.95M | 37.21M | 61.50M | 63.45M | 69.06M | 69.83M | 80.31M | 81.41M | 82.45M | 83.54M | 104.99M | 118.14M | 119.08M | |||
| Preferred Shares | 8.79M | 8.79M |